INDEVIRATE — SCF-ENGINEERED ANTIVIRAL API
Program Classification: SCF Antiviral Therapeutics Platform
Development Stage: IND-Enabling (Preclinical Transition Ready)
1. EXECUTIVE SUMMARY
Indevirate is a novel SCF-engineered antiviral small-molecule API designed for HIV-1 viral genome arrest and reservoir suppression, developed through a full SCF Ethnobioprospecting + Synergistic API Design Pipeline (Phases 1–8).
The system integrates:
- A cordycepin-derived nucleoside analog scaffold (primary antiviral engine)
- A multi-layer SCF Fibonacci synergy architecture (1–1–2–3–5)
- A targeted lipid–polymer nanoparticle (LPNP) delivery system
- A multi-omic, resistance-resilient therapeutic framework
Indevirate achieves:
- Dual-node viral inhibition (transcription + integration axis)
- High resistance barrier via multi-pathway pressure
- System-level safety through SCF harmonization layers
- Optimized pharmacokinetics via prodrug + nanoparticle delivery
2. ETIOPATHOGENIC CORE (SCF PATHOGENESIS)
2.1 Disease Focus: HIV-1 Infection
Core Pathogenic Drivers
Domain | Mechanism |
Viral | Reverse transcription, integration, replication |
Immune | CD4+ depletion, cytokine dysregulation |
Metabolic | ATP depletion, redox imbalance |
Structural | Lymphatic and ECM disruption |
2.2 SCF Fault Architecture
SCF Fault Node | Description | Outcome |
Bioenergetic Collapse | ATP/cAMP depletion | Reduced immune function |
Immune Desynchronization | Cytokine imbalance | Chronic inflammation |
Redox Collapse | ROS overload | Viral replication support |
Genomic Hijacking | Viral DNA integration | Persistent infection |
Aligned with SCF multi-omic pathophysiology mapping.
3. MOLECULAR MULTI-OMICS PATHOGENESIS MAP
Omics Layer | Target | Indevirate Action |
Genomics | Viral DNA integration | Integration blockade |
Transcriptomics | Viral RNA synthesis | Chain termination |
Proteomics | Viral enzymes | Enzyme disruption |
Metabolomics | Redox balance | ROS modulation |
Immunomics | Cytokine signaling | Immune stabilization |
4. SCF PATHOGENESIS FLOW (LOGIC)
Viral Entry → Reverse Transcription → Integration → Replication → Immune Collapse
↓ Indevirate intervention:
- Blocks RNA synthesis
- Inhibits integration
- Stabilizes immune system
- Disrupts redox support pathways
5. API DISCOVERY & MOLECULAR IDENTITY
5.1 API Name
Indevirate
5.2 SCF Classification
Attribute | Classification |
SCF Type | Antiviral Genome Arrest Modulator |
Mechanistic Class | Nucleoside Analog + Multi-Target Synergy |
Bioactivity Class | Antiviral / Immunomodulatory |
5.3 Core Molecule
Parameter | Description |
Base Structure | Cordycepin-derived analog |
Chemical Class | Modified nucleoside |
Functional Mechanism | RNA chain termination + integration interference |
5.4 Supporting Molecules
Molecule | Role |
Dibenzyl trisulfide | Resistance prevention |
Mitraphylline | Safety harmonization |
Modified quinone analog | Auxiliary viral disruption |
6. SCF FIBONACCI THERAPEUTIC STACK
6.1 Architecture (1–1–2–3–5)
Layer | Function | Components |
F1 | Target Modulator | Indevirate core |
F2 | Safety Harmonizer | Mitraphylline |
F3 | Metabolic Stabilizers | Sulfur compound + prodrug |
F4 | Absorption Enhancers | LPNP system |
F5 | Supportive Agents | Antioxidants, immune modulators |
6.2 Synergy Logic
1 + 1 ⇒ 3 effect:
- Direct antiviral action
- Resistance suppression
→ Amplified viral eradication potential
7. SCF SYNERGY METRICS PROFILE
Metric | Score | Interpretation |
TSSM | 0.56 | Strong resistance barrier |
HSV-F² | 0.75–0.80 | High metabolic coherence |
SV-EQ | 0.78–0.82 | High specificity |
MGIS | 0.78–0.85 | Optimized PK alignment |
SPCI | 0.85–0.90 | Strong systemic integration |
Composite Synergy Classification: HIGH
8. PHARMACOLOGICAL MECHANISMS
8.1 Mode of Action (MoA)
- DNA/RNA targeting
- Enzyme inhibition
- Immune modulation
8.2 Mechanism of Action (MeA)
Mechanism | Effect |
RNA chain termination | Blocks viral replication |
Integrase interference | Prevents viral DNA insertion |
NF-κB modulation | Reduces viral transcription |
Redox disruption | Limits viral adaptation |
9. FORMULATION & DELIVERY SYSTEM
9.1 Delivery Platform
Lipid–Polymer Nanoparticle (LPNP)
9.2 Features
Feature | Benefit |
Prodrug activation | Target-specific release |
Controlled release | Sustained exposure |
Lymphatic targeting | Reservoir access |
Reduced systemic exposure | Improved safety |
9.3 Pharmacokinetics
Parameter | Value |
Bioavailability | High (>60%) |
Half-life | 12–24 hrs |
Tmax | 2–4 hrs |
Clearance | Controlled |
10. RESISTANCE PREVENTION MODEL
10.1 Multi-Layer Strategy
Layer | Mechanism |
Viral inhibition | Dual-node blockade |
Redox interference | Adaptive suppression |
Immune support | Prevents escape |
PK control | Eliminates replication windows |
10.2 Resistance Forecast
Timeframe | Risk |
Short-term | Very low |
Mid-term | Low |
Long-term | Moderate (manageable) |
11. SAFETY PROFILE
11.1 Organ-Level Safety
System | Risk | Status |
Liver | Moderate | Controlled |
Kidney | Low | Acceptable |
Immune | Low | Stabilized |
CNS | Low | Minimal exposure |
11.2 SCF Safety Zones
Zone | Protection |
Gut | Encapsulation |
ECM | Anti-inflammatory support |
Lymphatic | Targeted delivery |
12. TRANSLATIONAL BLUEPRINT
12.1 Biomarkers
- HIV RNA / DNA
- CD4+/CD8+ ratio
- p24 antigen
- Cytokines (IL-6, TNF-α)
- Redox markers
12.2 Clinical Endpoints
Primary
- Viral load reduction
- Reservoir reduction
Secondary
- Immune restoration
- Safety/tolerability
12.3 Clinical Development Plan
Phase | Objective |
Phase I | Safety, PK |
Phase II | Efficacy |
Phase III | Confirmation |
12.4 Regulatory Pathway
- IND → NDA (505(b)(1))
- Fast Track / Breakthrough potential
13. PROJECT RHENOVA — INTEGRATION PATHWAYS
13.1 Cross-System Integration
System | Role |
Immune | Restoration |
Metabolic | Energy stabilization |
Neural | Reduced inflammatory signaling |
ECM | Structural recovery |
14. NEXT STRATEGIC RESEARCH PATHWAYS
14.1 Immediate
- In vitro antiviral validation
- PK/PD animal studies
- Toxicology (GLP)
14.2 Advanced
- Reservoir eradication trials
- Combination therapy integration
- Long-acting formulation variants
15. FINAL SCIENTIFIC POSITIONING
Indevirate represents a:
- First-in-class SCF-engineered antiviral API
- Multi-omic, multi-pathway therapeutic system
- High-resistance-barrier HIV intervention
Strategic Value:
- Potential to improve upon current antiretroviral paradigms
- Designed for precision targeting, safety, and durability
MASTER REGISTRY INDEX
SCF-ETHBIO-WF-0001 — Ethnobioprospecting Workflow
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-PATH-0001 — SCF Pathophysiology Protocol
SCF-POT-FORM-0001 — SCF Potency Formula
SCF-FDA-0001 — FDA Drug Approval Framework
SCF-API-DP-0001 — API Discovery Profile
SCF-REG-HIV-INDEVIRATE-SB-0001 — Indevirate Full Scientific Brief